Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoMentis has completed a Phase I study of its orally bioavailable, small-molecule beta-secretase inhibitor, CTS-21166, which is being developed as a disease-modifying treatment for Alzheimer's disease. Results from the study indicate that CTS-21166 is safe and well-tolerated.
Subscribe to our email newsletter
CoMentis said that pharmacodynamic proof of activity was achieved as subjects displayed a robust, sustained and dose-related reduction in plasma amyloid beta in both area-under-curve (AUC) reduction and peak reduction with effects lasting over 72 hours. Single dose administration of CTS-21166 produced a greater than 60% reduction of plasma amyloid beta measured either by AUC over 24 hours or as a maximal reduction relative to predose levels. The top doses of CTS-21166 further demonstrated a sustained reduction in AUC that was greater than 40% over 72 hours.
Henry Hsu, chief medical officer of CoMentis, said: “These data represent a significant advancement in the development of novel therapeutics to treat Alzheimer’s disease. CTS-21166 produced a rapid and significant reduction of plasma amyloid beta, a key biomarker that is believed to be involved in the pathogenesis of Alzheimer’s disease.”